Antitumour activity of TZT-1027, a novel Dolastatin 10 derivative

Japanese Journal of Cancer Research

Volumn 88, Issue 3, 1997, Pages 316-327

  Kobayashi, Motohiro ^a   Natsume, Tsugitaka ^a   Tamaoki, Satoru ^a   Watanabe, Jun Ichi ^a   Asano, Hajime ^a   Mikami, Takashi ^a   Miyasaka, Katsuhiko ^a   Miyazaki, Koichi ^a   Gondo, Masaaki ^a   Sakakibara, Kyoichi ^a   Tsukagoshi, Shigeru ^b  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

Antitumour activity; Dolastatin 10; Microtubule; Tubulin binder; TZT 1027

Indexed keywords

ANTINEOPLASTIC AGENT; AURISTATIN PE; CISPLATIN; DOLASTATIN 10; DOXORUBICIN; FLUOROURACIL; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG; VINCRISTINE; OLIGOPEPTIDE; SOBLIDOTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER GRAFT; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA P 388; LUNG CARCINOMA; MELANOMA B16; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SARCOMA; SWINE; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; C57BL MOUSE; CELL DIVISION; COMPARATIVE STUDY; CROSS BREEDING; DBA MOUSE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; LUNG TUMOR; MOLLUSC; NUDE MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CISPLATIN; CROSSES, GENETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LEUKEMIA P388; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; MOLLUSCA; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030612225     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00383.x     Document Type: Article

References (33)

1. Pettit, G. R., Kamano, Y., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B. and Bontems, R. J. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc., 109, 6883-6885 (1987).
2. Pettit, G. R., Singh, S. B., Hogan, F., Lloyd-Williams, P., Herald, D. L., Burkett, D. D. and Clewlow, P. J. The absolute configuration and synthesis of natural (-)dolastatin 10. J. Am. Chem. Soc., 111, 5463-5465 (1987).
3. Pettit, G. R., Kamano, Y., Herald, C. L., Fujii, Y., Kizu, H., Boyd, M. R., Boettner, F. E., Doubek, D. L. Schmidt, J. M., Chapuis, J. C. and Michel, C. Isolation of dolastatins 10-15 from the marine mollusk Dolabella auricularia. Tetrahedron, 49, 9151-9170 (1993).
4. Hamada, Y., Hayashi, K. and Shioiri, T. Efficient stereoselective synthesis of dolastatin 10, an antineoplastic peptide from a sea hare. Tetrahedron Lett., 32, 931-934 (1991).
5. Bai, R., Pettit, G. R., Hamel, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Biochem. Pharmacol., 39, 1941-1949 (1990).
6. Bai, R., Pettit, R. R., Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and Vinca alkaloid sites. J. Biol. Chem., 265, 17141-17149 (1990).
7. Ludueña, R. F., Roach, M. C., Prasad, V. and Pettit, G. R. Interaction of dolastatin 10 with bovine brain tubulin. Biochem. Pharmacol., 43, 539-543 (1992).
8. Li, Y., Kobayashi, Y., Hashimoto, Y., Shirai, R., Hirata, A., Hayashi, K., Hamada, Y., Shioiri, T. and Iwasaki, S. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding. Chem. Biol. Interact., 93, 175-183 (1994).
9. Depierre, A., Lemarie, E., Dabouis, G., Garnier, G., Jacoulet, P. and Dalphin, J. C. Efficacy of navelbine (NVB) in non-small-cell lung cancer (NSCLC). Am. J. Clin. Oncol., 14, 115-119 (1991).
10. Yokoyama, A., Furuse, K., Niitani, H. and other members of the Navelbine Study Group: Multi-institutional phase II study of navelbine (vinorelbine) in non-small-cell lung cancer. Am. Soc. Clin. Oncol., 11, 957 (1992).
11. Canobbio, L., Boccardo, F., Pastorino, G., Brema, F., Martini, C., Resasco, M. and Santi, L. Phase-II study of navelbine in advanced breast carcinoma. Semin. Oncol., 16 (Suppl. 4), 33-36 (1989).
12. Miyazaki, K., Kobayashi, M., Natsume, T., Gondo, M., Mikami, T., Sakakibara, K. and Tsukagoshi, S. Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem. Pharm. Bull., 43, 1706-1718 (1995).
13. Yoshino, H., Ueda, N., Niijima, J., Sugumi, J., Kotake, Y., Okada, T., Koyanagi, N., Asada, M., Yoshimatsu, K. and Kitoh, K. Novel sulfonamides as potential, systemically active antitumor agents. J. Med. Chem., 35, 2496-2497 (1992).
14. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41, 1967-1972 (1981).
15. Inaba, M., Kobayashi, H., Sakurai, Y. and Johnson, R. K. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res., 39, 2200-2203 (1979).
16. Tashiro, T., Kawada, Y., Sakurai, Y. and Kida, Y. Anti tumor activity of a new platinum complex, oxalato (transl-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed. Pharmacother., 43, 251-260 (1989).
17. Tashiro, T. and Sato, Y. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in mouse leukemia cell lines. Jpn. J. Cancer Res., 83, 219-225 (1992).
18. Inaba, M., Fujikura, R. and Sakurai, Y. Comparative study on in vivo development of resistance to various classes of antitumor agents in P388 leukemia. Gann, 70, 607-613 (1979).
19. Mitsuhashi, J. and Inaba, M. Mechanism for resistance to 5-fluorouracil in P388 leukemia cells. J. PharmacobioDyn., 14, 577-581 (1991).
20. Geran, R. J., Greenberg, N. R., MacDonald, H. M., Schumacher, A. M., Abott, B. Y. Protocols for screening chemical agents and natural products against animal tumor and other biological systems. Cancer Chemother. Rep., Part 3, 3, 1-103 (1972).
21. Tashiro, T., Inaba, M., Kobayashi, T., Sakurai, Y., Maruo, K., Ohnishi, Y., Ueyama, Y., Nomura, T. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother. Pharmacol., 24, 187-192 (1989).
22. Shelanski, M. L., Gaskin, F. and Cantor, C. R. Microtubule assembly in the absence of added nucleotides. Proc. Natl Acad. Sci. USA, 70, 765-768 (1973).
23. Ling, V., Kartner, N., Sudo, T., Siminovitch, L. and Riordan, J. R. Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat. Rep., 67, 869-874 (1983).
24. Douros, J. and Suffness, M. New natural products under development at the National Cancer Institute. Recent Results Cancer Res., 76, 153-175 (1981).
25. Bissery, M.-C, Guénard, D., Guéritte-Voegelein, F. and Lavelle, F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res., 51, 4845-4852 (1991).
26. Toppmeyer, D. L., Slapak, C. A., Crop, J. and Kufe, D. W. Role of P-glycoprotein in dolastatin 10 resistance. Biochem. Pharmacol., 48, 609-612 (1994).
27. Maral, R., Bourut, C., Chenu, E. and Mathe, G. Experimental antitumor activity of 5'-nor anhydrovinblastine, navelbine. Cancer Lett., 22, 49-54 (1989).
28. Tsuruo, T., Oh-hara, T., Iida, H., Tsukagoshi, S., Sato, Z., Matsuda, I., Iwasaki, S., Okuda, S., Shimizu, F., Sasagawa, K., Fukami, M., Fukuda, K. and Arakawa, M. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res., 46, 381-385 (1986).
29. Hamel, E. Natural products which interact with tubulin in the Vinca domain: maytansine, rhizoxin, phomopsin A, dolastatin 10 and 15 and halichondrin B. Pharmacol. Ther., 55, 31-51 (1992).
30. Bai, R., Taylor, G. F., Schmidt, J. M., Williams, M. D., Kepler, J. A., Pettit, G. R. and Hamel, E. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions. Mol. Pharmacol., 47, 965-976 (1995).
31. Bai, R., Friedman, S. J., Pettit, G. R. and Hamel, E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem. Pharmacol., 43, 2637-2645 (1992).
32. de Arruda, M., Cocchiaro, C. A., Nelson, C. M., Grinnell, C. M., Janssen, B., Haupt, A. and Barlozzari, T. LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res., 55, 3085-3092 (1995).
33. Jordan, M. A., Thrower, D. and Wilson, L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res., 51, 2212-2222 (1991).